NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02317276,A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal,https://clinicaltrials.gov/study/NCT02317276,GNE-AD,TERMINATED,"The purpose of this study is to assess the differential expression of AD biomarkers in serum, plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD patients in the presence of TCS and after withdrawal from TCS.",YES,"Dermatitis, Atopic",DRUG: Triamcinolone 0.1%,"Change in Blood and Tissue Levels of Biomarkers Following Treatment of Atopic Dermatitis With Topical Corticosteroids., The blood and skin biomarkers to be evaluated include but are not limited to eosinophils, Immunoglobulin E (IgE), Interleukin 13 (IL-13), Chemokine ligand 13 (CCL-13), and Chemokine ligand 17 (CCL-17). These biomarkers will be evaluated for differential gene expression and protein levels in samples obtained from atopic dermatitis patients on and off topical corticosteroid treatment., Baseline to Week 8",,,"University of California, San Francisco","Genentech, Inc.",ALL,"ADULT, OLDER_ADULT",PHASE4,11,OTHER,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,GNE AD 431,2014-12,2017-04-06,2017-04-06,2014-12-15,2018-11-26,2019-01-24,"UCSF Dermatology, San Francisco, California, 94115, United States","Study Protocol and Statistical Analysis Plan, https://storage.googleapis.com/ctgov2-large-docs/76/NCT02317276/Prot_SAP_000.pdf"
